---
authors:
- Ebell, Mark H
category: Case Study
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37054429/
file_path: 2023/04/liraglutide-is-probably-the-best-second-drug-to-prevent-card.md
issue: '4'
keywords:
- Diabetes Mellitus, Type 2
- Humans
- Cardiovascular Diseases
- Diabetes
- Metformin
- Liraglutide
- Treatment Outcome
- Drug Therapy, Combination
- Blood Glucose
- Hypoglycemic Agents
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Metformin
- Diabetes Mellitus, Type 2
- Liraglutide
- Hypoglycemic Agents
- Cardiovascular Diseases
- Drug Therapy, Combination
- Blood Glucose
- Treatment Outcome
original_format: PubMed
pages: '434'
patient_population: Adults
peer_reviewed: true
pmid: '37054429'
processed_date: '2025-07-30'
publication_date: '2023-04-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events
  in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '107'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37054429'
  title: Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events
    in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
    affiliation: University of Georgia, Athens, Ga.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '107'
    issue: '4'
  publication_info:
    year: '2023'
    month: '04'
    full_date: '2023-04-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Metformin
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
    qualifiers:
    - qualifier: complications
      major_topic: false
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Liraglutide
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Hypoglycemic Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Cardiovascular Diseases
    major_topic: true
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
    - qualifier: chemically induced
      major_topic: false
  - descriptor: Drug Therapy, Combination
    major_topic: false
  - descriptor: Blood Glucose
    major_topic: false
  - descriptor: Treatment Outcome
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '37054429'
  title: Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events
    in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Apr
- pmid: '29197387'
  title: Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients
    complicated with coronary artery disease.
  authors:
  - name: Liu Y
    authtype: Author
    clusterid: ''
  - name: Jiang X
    authtype: Author
    clusterid: ''
  - name: Chen X
    authtype: Author
    clusterid: ''
  source: Lipids Health Dis
  pubdate: 2017 Dec 2
- pmid: '31326727'
  title: 'Liraglutide in combination with metformin may improve the atherogenic lipid
    profile and decrease C-reactive protein level in statin treated obese patients
    with coronary artery disease and newly diagnosed type 2 diabetes: A randomized
    trial.'
  authors:
  - name: Anholm C
    authtype: Author
    clusterid: ''
  - name: Kumarathurai P
    authtype: Author
    clusterid: ''
  - name: Pedersen LR
    authtype: Author
    clusterid: ''
  - name: Samkani A
    authtype: Author
    clusterid: ''
  - name: Walzem RL
    authtype: Author
    clusterid: ''
  - name: Nielsen OW
    authtype: Author
    clusterid: ''
  - name: Kristiansen OP
    authtype: Author
    clusterid: ''
  - name: Fenger M
    authtype: Author
    clusterid: ''
  - name: Madsbad S
    authtype: Author
    clusterid: ''
  - name: Sajadieh A
    authtype: Author
    clusterid: ''
  - name: Haugaard SB
    authtype: Author
    clusterid: ''
  source: Atherosclerosis
  pubdate: 2019 Sep
- pmid: '31034184'
  title: Liraglutide in Children and Adolescents with Type 2 Diabetes.
  authors:
  - name: Tamborlane WV
    authtype: Author
    clusterid: ''
  - name: Barrientos-PÃ©rez M
    authtype: Author
    clusterid: ''
  - name: Fainberg U
    authtype: Author
    clusterid: ''
  - name: Frimer-Larsen H
    authtype: Author
    clusterid: ''
  - name: Hafez M
    authtype: Author
    clusterid: ''
  - name: Hale PM
    authtype: Author
    clusterid: ''
  - name: Jalaludin MY
    authtype: Author
    clusterid: ''
  - name: Kovarenko M
    authtype: Author
    clusterid: ''
  - name: Libman I
    authtype: Author
    clusterid: ''
  - name: Lynch JL
    authtype: Author
    clusterid: ''
  - name: Rao P
    authtype: Author
    clusterid: ''
  - name: Shehadeh N
    authtype: Author
    clusterid: ''
  - name: Turan S
    authtype: Author
    clusterid: ''
  - name: Weghuber D
    authtype: Author
    clusterid: ''
  - name: Barrett T
    authtype: Author
    clusterid: ''
  - name: Ellipse Trial Investigators
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2019 Aug 15
- pmid: '28071177'
  title: Liraglutide and cardiovascular outcomes in type 2 diabetes.
  authors:
  - name: Jones B
    authtype: Author
    clusterid: ''
  source: Ann Clin Biochem
  pubdate: 2016 Nov
---

# Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 107, No. 4 | 2023-04-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37054429/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Metformin, Diabetes Mellitus, Type 2, Liraglutide, Hypoglycemic Agents, Cardiovascular Diseases, Drug Therapy, Combination, Blood Glucose, Treatment Outcome

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37054429/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
